Estimating the Causal Effect of Entry on Generic Drug Prices Using Hatch–Waxman Exclusivity

Article

Abstract

Competition among generics helps keep drug prices low and control medical costs. Good estimates of the effect on price of the entry of another generic competitor would inform competition policy and test oligopoly theories. However, identifying the causal effect of entry is difficult since the number of firms that compete in a market is endogenously determined. We exploit provisions of the 1984 Hatch–Waxman Act to identify a causal effect. We find that ignoring endogenous selection into generic drug markets imparts a significant downward bias to the estimates of the effects of two and three competitors on generic drug prices.

Keywords

Generic entry Pharmaceutical Prescription drugs Price competition 

JEL Classification

L11 L13 L6 

Notes

Acknowledgements

We thank David Schmidt and Steven Tenn for invaluable advice. We also thank Viola Chen, Abe Dunn, Daniel Hosken, Karen Goldman, Kubo Kensuke, Chris Metcalf, Elizabeth Schneirov, Joel Schrag, Christopher Snyder, Aileen Thompson, Mike Vita, and Nathan Wilson for providing helpful comments. Greg Kuczura provided outstanding research assistance. The views expressed in this paper are those of the authors and do not necessarily represent the views of the Federal Trade Commission, any individual Commissioner, the Office of the Comptroller of the Currency, or the U.S. Department of the Treasury.

References

  1. Bergemann, D., & Valimaki, J. (2006). Dynamic pricing of new experience goods. Journal of Political Economy, 114(4), 713–743.CrossRefGoogle Scholar
  2. Berndt, E. R., & Aitken, M. L. (2011). Brand loyalty, generic entry, and price competition in the quarter century after the 1984 Waxman–Hatch legislation. International Journal of the Economics of Business, 18(2), 177–201.CrossRefGoogle Scholar
  3. Caves, R. E., Whinston, M. D., & Hurwitz, M. A. (1991). Patent expiration, entry, and competition in the U.S. pharmaceutical industry. In Brookings papers on economic activity: Microeconomics (pp. 1–66).Google Scholar
  4. Danzon, P. M., & Chao, L. (2000). Does regulation drive out competition in pharmaceutical markets? Journal of Law and Economics, 43(4), 311–357.CrossRefGoogle Scholar
  5. Davis, S. J., Murphy, K. M., & Topel, R. H. (2004). Entry, pricing, and product design in an initially monopolized market. Journal of Political Economy, 112(S1), 188–225.CrossRefGoogle Scholar
  6. Federal Trade Commission. (2011). Authorized generic drugs: Short-term effects and long-term impact. https://www.ftc.gov/reports/authorized-generic-drugs-short-term-effects-long-term-impact-report-federal-tradecommission. Accessed 06 April 2018.
  7. Frank, R. G., & Salkever, D. S. (1992). Pricing patent loss and the market for pharmaceuticals. Southern Economic Journal, 59(2), 165–179.CrossRefGoogle Scholar
  8. Frank, R. G., & Salkever, D. S. (1997). Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy, 6(1), 75–90.CrossRefGoogle Scholar
  9. Grabowski, H. G., & Vernon, J. M. (1992). Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. Journal of Law and Economics, 35(2), 331–350.CrossRefGoogle Scholar
  10. Kyle, M. (2006). The role of firm characteristics in pharmaceutical product launches. RAND Journal of Economics, 37(3), 602–618.CrossRefGoogle Scholar
  11. Panattoni, L. E. (2011). The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. Journal of Health Economics, 30(1), 126–145.CrossRefGoogle Scholar
  12. Regan, T. L. (2008). Generic entry, price competition, and market segmentation in the prescription drug market. International Journal of Industrial Organization, 26(4), 930–948.CrossRefGoogle Scholar
  13. Reiffen, D., & Ward, M. R. (2005). Generic drug industry dynamics. Review of Economics and Statistics, 87(1), 37–49.CrossRefGoogle Scholar
  14. Reiffen, D., & Ward, M. R. (2007). Branded generics’ as a strategy to limit cannibalization of pharmaceutical markets. Managerial and Decision Economics, 28, 258–265.CrossRefGoogle Scholar
  15. Scott Morton, F. M. (1999). Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics, 30(3), 421–440.CrossRefGoogle Scholar
  16. Tenn, S., & Wendling, B. W. (2014). Entry threats and pricing in the generic drug industry. Review of Economics and Statistics, 96(2), 214–228.CrossRefGoogle Scholar
  17. Wiggins, S. N., & Maness, R. (2004). Price competition in pharmaceuticals: The case of anti-infectives. Economic Inquiry, 42(2), 247–263.CrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  1. 1.Office of the Comptroller of the CurrencyU.S. Department of the TreasuryWashingtonUSA
  2. 2.Federal Trade CommissionWashingtonUSA

Personalised recommendations